In this Viewpoint, 2016 Lasker Award winners Ralf Bartenschlager, Charles Rice, and Michael Sofia discuss their work developing a system to study the replication of hepatitis C virus and a class of antivirals to treat the infection.
This Viewpoint calls for government support for providing direct–acting antiviral treatment to American Indian/Alaska Native population, which is disproportionately infected by hepatitis C virus.
This Viewpoint discusses potential opportunities to advance health care in the US criminal justice system based on recent developments.
This randomized trial reports high rates of sustained virologic response in the first part of a open-label study of ombitasvir, paritaprevir (co-dosed with ritonavir), and dasabuvir with ribavirin for 63 patients with hepatitis C virus genotype 1 and human immunodeficiency virus 1 co-infection.
This pilot study reports high rates of posttreatment sustained virologic response after use of combined ledipasvir and sofosbuvir among patients co-infected with hepatitis C virus genotype 1 and human immunodeficiency virus.
Kohli and coauthors review the safety, efficacy, and tolerability of current approved interferon-based regimens and oral interferon-free regimens for treating hepatitis C virus infection and provide treatment recommendations for specialists and generalists based on published evidence.
The PHOTON-1 investigators report that, after 12 or 24 weeks of treatment patients coinfected with HIV and hepatitis C virus who received an oral, interferon-free combination of sofosbuvir and ribavirin for 12 or 24 weeks had high rates of sustained virologic response.
To assess the addition of sofosbuvir to ribavirin to treat liver disease in patients with hepatitis C virus, especially among patients with unfavorable treatment characteristics—black race, genotype 1a, advanced liver fibrosis, and obesity—Osinusi and coauthors conducted a 2-part, single-center, randomized open-label trial involving 60 patients. They compared the combination treatment of weight-based or low-dose ribavirin treatment plus 400 mg/d of sofosbuvir for 24 weeks.